Massini Merzkani is a Nephrology physician affiliated with Washington University in St. Louis. OpenAlex indexes 48 publications with 448 citations (h-index 11).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4921 Parkview Pl
Div Im Nephrology, Ste 5c
Saint Louis, MO 631101032
Telephone
314-362-7603Registry record last updated 17 Apr 2025.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Travere Therapeutics, Inc.Program year20242 payments
- ABBVIE INC.Program year20231 payment
- Veloxis Pharmaceuticals, Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
45.8%Statin12.7%Atorvastatin Calcium85%Rosuvastatin Calcium7%Pravastatin Sodium6%Simvastatin2%Part D<11 patientsBeta blocker10.8%Carvedilol80%Metoprolol Tartrate10%Labetalol Hcl4%Metoprolol Succinate3%Propranolol Hcl2%Atenolol1%Part D<11 patients+ 15 more classes in this area
Metabolism & gastrointestinal
29.8%Corticosteroid12.8%Prednisone100%Part D≥225 patientsProton pump inhibitor6.6%Pantoprazole Sodium69%Omeprazole28%Esomeprazole Magnesium4%Part D<11 patients+ 9 more classes in this area
Anti-infectives
9.8%Short-acting sulfonamides6.4%Sulfamethoxazole-Trimethoprim100%Part D≥123 patientsCytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor2.2%Valganciclovir Hcl100%Part D≥61 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A Case of Successful Kidney Transplant‐Alone in Primary Hyperoxaluria Type 1 Using Lumasiran
Clinical Transplantation
2026 - Elevations in Donor-Derived Cell-Free DNA and Allograft Outcomes in Kidney Transplantation
Journal of the American Society of Nephrology
2026 - Thrombotic Microangiopathy After Kidney Transplantation: Insights Into Genetic Etiology and Clinical Outcomes
Kidney International Reports
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Timothy Ley, MD
Washington University in St. Louis
David Gutmann, MD
Washington University in St. Louis
Randall Bateman, MD
Washington University in St. Louis
Victoria Fraser, MD
Washington University in St. Louis
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”